ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy

Interferon (IFN)-β is the first-line disease management choice in multiple sclerosis (MS) with profound effects; however, in up to 50% of patients, clinical response does not occur. Ascertaining the responding state, need a long-term clinical follow-up, and this may lead to delay in use of other eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhr, Fatemeh, Shaygannejad, Vahid, Khorrami, Mehdi, Saberi, Leila, Mirmosayyeb, Omid, Sadeghi, Erfan, Kheirollahi, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370467/
https://www.ncbi.nlm.nih.gov/pubmed/37501759
http://dx.doi.org/10.1055/s-0043-1771001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370467/
https://www.ncbi.nlm.nih.gov/pubmed/37501759
http://dx.doi.org/10.1055/s-0043-1771001

Ejemplares similares